The prize is to be awarded to an internationally recognized scientist, whose activities or published accounts have made an outstanding contribution in the field of flow chemistry, microfluidics, micro fabrication, and micro systems engineering in academia or industry.
The Prize, of USD 7 500, has been established by a generous gift from the Hungarian Technology company ThalesNano Inc. to acknowledge the key role that flow chemistry plays towards the improvement of chemical processes.
Applications should be received by nomination only, with just one person acting as the nominator, with a total of five (5) individuals as referees overall. The package must be submitted electronically and should contain a complete resume, a professional autobiography of not more than two pages, and a one-page summary of what the individual considers to be his/her activities, accomplishments and/or publications that have had the most significant impact upon the field of Flow Chemistry. The material will be forwarded confidentially to an independent selection committee appointed by the IUPAC Committee on Chemistry and Industry.
Nomination materials should be submitted by 31 January 2018 to the chair of the IUPAC Committee on Chemistry and Industry, Dr. Carolyn Ribes, by email at: cribes@dow.com https://iupac.org/what-we-do/awards/
Holý Chemistry
The prevention and treatment of viral infectious diseases, including the common cold, influenza, hepatitis, yellow fever, and Acquired Immunodeficiency Syndrome (AIDS), continues to challenge public health systems throughout the world. A huge amount of resources is dedicated to understanding the molecular basis of these afflictions and devising the means to prevent, treat, or cure them. Chemistry, biology, medicine, and related fields play an important role in basic and applied research aimed at accomplishing these goals.
The stamp illustrated in this note honors Antonín Holý An indefatigable researcher and prolific writer, Holý was the author or co-author of some 600 publications and 60 patents, many of them achieved together with his longtime collaborator Erik De Clercq, a renowned immunologist and microbiologist at the Rega Institute for Medical Research at the Catholic University in Leuven, Belgium. Their concerted work led to the discovery of important drugs, such as tenofovir disoproxil, which was approved by the U.S. Food and Drug Administration in 2001 to prevent and treat HIV, often in combination with other antiretroviral agents, and in 2008 for the treatment of chronic hepatitis B. Sold under the trade name Viread, tenofovir disoproxil is a nucleotide reverse transcriptase inhibitor that works by decreasing the ability of the viruses to replicate. Significantly, it is included in the World Health Organization's List of Essential Medicines, a compilation of the most important drugs needed in a health system.
For a personal account on the development of antiviral drugs during the past 50 years, see: De Clercq, E. Acta Pharm Sin. B. 2015, 5:520-543. Written by Daniel Rabinovich <drabinov@uncc.edu>
